Maria Chiara Siciliano,Giorgio Bertolazzi,Gaia Morello,Salvatore Tornambè,Marcello Del Corvo,Massimo Granai,Maria Rosaria Sapienza,Ciara I Leahy,Eanna Fennell,Beatrice Belmonte,Felice Arcuri,Margherita Vannucchi,Virginia Mancini,Raffaella Guazzo,Roberto Boccacci,Noel Onyango,Joshua Nyagol,Raffaella Santi,Gioia Di Stefano,Domenico Ferrara,Cristiana Bellan,Teresa Marafioti,German Ott,Reiner Siebert,Leticia Quintanilla-Fend,Falko Fend,Paul G Murray,Claudio Tripodo,Stefano Aldo Pileri,Stefano Lazzi,Lorenzo Leoncini

Abstract:Burkitt lymphoma (BL) is characterized by tumor microenvironment (TME) in which macrophages represent the main component, determining a distinct histological appearance known as "starry sky" pattern. However, in some instances, BL may exhibit a granulomatous reaction that has been previously linked to a favorable prognosis and spontaneous regression. The aim of our study was to deeply characterize the immune landscape of 7 cases of EBV + BL with granulomatous reaction compared to 8 cases of EBV + BL and 8 EBV- BL, both with typical "starry sky" pattern, by Gene expression profiling performed on the NanoString nCounter platform. Subsequently, the data were validated by multiplex and combined immunostaining. Based on unsupervised clustering of differentially expressed genes, BL samples formed 3 distinct clusters differentially enriched in BL with a diffuse granulomatous reaction (cluster 1), EBV+ BL with typical starry sky pattern (Cluster 2), EBV - BL with typical "starry sky" (cluster 3). We observed variations in the immune response signature among BL with granulomatous reaction and BL with typical "starry sky", both EBV + and EBV -. The TME signature in BL with diffuse granulomatous reaction showed a proinflammatory response, while BLs with "starry sky" were characterized by up-regulation of M2- polarization and pro-tumor response. Moreover, the analysis of additional signatures revealed an up-regulation of Dark zone-signature and epigenetic-signature in BL with typical "starry sky". Tumor associated macrophages (TAM) and epigenetic regulators may be promising targets for additional therapies in BL lymphoma opening novel immunotherapeutic strategies.

Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behaviour.